Jaguar Health, Inc.

Informe acción NasdaqCM:JAGX

Capitalización de mercado: US$9.6m

Jaguar Health Dirección

Dirección controles de criterios 4/4

El CEO de Jaguar Health es Lisa Conte , nombrado en Jun 2013, tiene una permanencia de 11.42 años. compensación anual total es $815.85K, compuesta por 70.6% salario y 29.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.18% de las acciones de la empresa, por valor de $17.29K. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 6.7 años, respectivamente.

Información clave

Lisa Conte

Chief Executive Officer (CEO)

US$815.9k

Compensación total

Porcentaje del salario del CEO70.6%
Permanencia del CEO11.4yrs
Participación del CEO0.2%
Permanencia media de la dirección3.9yrs
Promedio de permanencia en la Junta Directiva6.7yrs

Actualizaciones recientes de la dirección

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%

Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Oct 17

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Aug 25

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Aug 19

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Aug 09

Jaguar stock rises on license deal with SynWorld for Canalevia in China

Jun 29

Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory

Mar 07

Jaguar Health shares jumps 13% after pricing $15M direct offering

Jan 13

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jan 11

Jaguar Health leaps higher in new year

Jan 05

Jaguar Health inks second Mytesi royalties agreement for $6M

Dec 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Dec 02
Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Nov 30

Jaguar Health EPS misses by $0.10, misses on revenue

Nov 16

Jaguar Health receives positive Nasdaq listing determination

Oct 29

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lisa Conte en comparación con los beneficios de Jaguar Health?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$38m

Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$38m

Dec 31 2023US$816kUS$576k

-US$41m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$44m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$1mUS$603k

-US$47m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$3mUS$527k

-US$53m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$1mUS$500k

-US$39m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$45m

Dec 31 2019US$1mUS$500k

-US$45m

Sep 30 2019n/an/a

-US$48m

Jun 30 2019n/an/a

-US$43m

Mar 31 2019n/an/a

-US$34m

Dec 31 2018US$1mUS$480k

-US$32m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

-US$30m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$643kUS$440k

-US$22m

Compensación vs. Mercado: La compensación total ($USD815.85K) de Lisa está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD652.28K).

Compensación vs. Ingresos: La compensación de Lisa ha sido consistente con los resultados de la empresa en el último año.


CEO

Lisa Conte (65 yo)

11.4yrs

Permanencia

US$815,854

Compensación

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Lisa Conte
Founder11.4yrsUS$815.85k0.18%
$ 17.3k
Pravin Chaturvedi
Chief Scientific Officer & Chair of Scientific Advisory Board2.7yrsUS$627.13k0.054%
$ 5.2k
Jonathan Wolin
Chief of Staff6yrsUS$562.79k0.054%
$ 5.2k
Steven King
Chief of Sustainable Supply10.2yrsUS$491.54k0.054%
$ 5.1k
Carol Lizak
Chief Financial Officer4.7yrssin datos0.046%
$ 4.5k
Peter Hodge
Senior Director of Investor Relationsno datasin datossin datos
Karen Brunke
Executive VP of Corporate & Business Development3.2yrssin datossin datos
David Sesin
Chief Manufacturing Officerno datasin datossin datos
Ian Wendt
Chief Commercial Officer3.9yrsUS$557.90ksin datos
Massimo Radaelli
President of Jaguar Internationalless than a yearsin datossin datos
Catherine Collis
Senior Vice President of Growth Strategyless than a yearsin datossin datos
Darlene Horton
Chief Medical Officerno datasin datossin datos

3.9yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de JAGX se considera experimentado (3.9 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Lisa Conte
Founder11.4yrsUS$815.85k0.18%
$ 17.3k
Pravin Chaturvedi
Chief Scientific Officer & Chair of Scientific Advisory Board7.5yrsUS$627.13k0.054%
$ 5.2k
James Bochnowski
Independent Chairman10.8yrsUS$140.98k0.00041%
$ 39.4
John Micek
Independent Director8.6yrsUS$101.68k0.00024%
$ 23.1
Anula Jayasuriya
Independent Director2.3yrsUS$77.61k0.00031%
$ 29.8
Jonathan Siegel
Independent Director6.7yrsUS$104.18k0.00026%
$ 25.0
Sandra Swain
Member of Scientific Advisory Board1.8yrssin datossin datos
Kelly Shanahan
Scientific Advisory Board1.7yrssin datossin datos
Stacey Tinianov
Member of Scientific Advisory Board1.5yrssin datossin datos

6.7yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de JAGX se considera experimentada (6.7 años de antigüedad promedio).